Severe Drug-Induced Liver Injury as an Adverse Drug Event of Antibiotics: A Case Report and Review of the Literature
We report the case of a young patient who experienced a drug-induced liver injury resulting in life-threatening acute liver failure after treatment with different antibiotics (amoxicillin, ciprofloxacin, cefazolin, clindamycin) and acetaminophen, or a combination of these drugs. Moreover, we provide an overview of the hepatotoxic potential of these drugs.Chemotherapy 2017;62:367-373 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research
Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice
Conclusion: NSCLC patients treated with nivolumab as second-line therapy had a longer PFS compared to patients treated with docetaxel in a health care environment.Chemotherapy 2017;62:374-380 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research
α-Pinene Inhibits Human Prostate Cancer Growth in a Mouse Xenograft Model
Conclusions: These data strongly suggest that α-pinene inhibits prostate cancer growth in a xenograft model and may be an effective therapeutic agent for prostate cancer treatment.Chemotherapy 2018;63:1-7 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research
Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice
Conclusion: NSCLC patients treated with nivolumab as second-line therapy had a longer PFS compared to patients treated with docetaxel in a health care environment.Chemotherapy 2017;62:374-380 (Source: Chemotherapy)
Source: Chemotherapy - October 18, 2017 Category: Cancer & Oncology Source Type: research
Severe Drug-Induced Liver Injury as an Adverse Drug Event of Antibiotics: A Case Report and Review of the Literature
We report the case of a young patient who experienced a drug-induced liver injury resulting in life-threatening acute liver failure after treatment with different antibiotics (amoxicillin, ciprofloxacin, cefazolin, clindamycin) and acetaminophen, or a combination of these drugs. Moreover, we provide an overview of the hepatotoxic potential of these drugs.Chemotherapy 2017;62:367-373 (Source: Chemotherapy)
Source: Chemotherapy - September 21, 2017 Category: Cancer & Oncology Source Type: research
Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer
Conclusions: Combination therapy with capecitabine and cisplatin may be an option for second-line chemotherapy in some of patients with advanced BTC.Chemotherapy 2017;62:361-366 (Source: Chemotherapy)
Source: Chemotherapy - August 25, 2017 Category: Cancer & Oncology Source Type: research
The Effect of Tegafur-Uracil on Survival in T Categories as Defined in the Eighth Edition of the TNM Classification: An Exploratory Analysis of Postoperative Adjuvant Tegafur-Uracil on Survival in Patients with Adenocarcinoma of the Lung
Background: Tegafur-uracil (UFT) improves survival in patients with stage I adenocarcinoma of the lung. We evaluated the effect of UFT on survival in maximum primary tumor diameter (T) categories as defined in the eighth edition of the TNM Classification (TNM8).Methods: Tumors were subgrouped on the basis of T category (TNM8) as follows: T1a, T ≤1 cm; T1b, 1 (Source: Chemotherapy)
Source: Chemotherapy - August 17, 2017 Category: Cancer & Oncology Source Type: research
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant
We describe the case of a patient with Philadelphia-positive acute lymphoblastic leukemia treated with dasatinib plus steroids as first-line therapy, who achieved a major molecular response (MMR) before undergoing matched, unrelated donor allogeneic stem cell transplant. Eleven months after the transplant, she experienced molecular relapse. Mutational screening showed negativity for the T315I mutation, The patient underwent a salvage chemotherapy regimen with clofarabine + cyclophosphamide + steroids and ponatinib (clofarabine 70 mg i.v., days 1-5, cyclophosphamide 700 mg i.v., days 1-5, and ponatinib 45 mg p.o., daily sta...
Source: Chemotherapy - August 15, 2017 Category: Cancer & Oncology Source Type: research
Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib
We report a case of a chronic myeloid leukemia patient showing progressive bone marrow fibrosis and anemia during imatinib therapy. Given the loss of major molecular response, we switched treatment to dasatinib 100 mg daily, observing a reduction in BCR-ABL transcript, a significant improvement of anemia, and a gradual disappearance of fibrosis. After 7 years of dasatinib therapy the patient maintains a complete cytogenetic response and a deep molecular response; the last bone biopsy confirmed the absence of fibrosis.Chemotherapy 2017;62:350-352 (Source: Chemotherapy)
Source: Chemotherapy - July 25, 2017 Category: Cancer & Oncology Source Type: research
Colistin Resistance in KPC-2- and SHV-5-Producing Klebsiella pneumoniae Clinical Isolates in Bulgaria
Conclusions: Although colistin use in Bulgaria only started moderately during 2014, the findings of the current study notify the appearance of colistin resistance among carbapenemase-producingKlebsiella species in another European region.Chemotherapy 2017;62:339-342 (Source: Chemotherapy)
Source: Chemotherapy - July 24, 2017 Category: Cancer & Oncology Source Type: research
Colistin Resistance in KPC-2- and SHV-5-Producing < b > < i > Klebsiella pneumoniae < /i > < /b > Clinical Isolates in Bulgaria
Conclusions: Although colistin use in Bulgaria only started moderately during 2014, the findings of the current study notify the appearance of colistin resistance among carbapenemase-producingKlebsiella species in another European region.Chemotherapy 2017;62:339-342 (Source: Chemotherapy)
Source: Chemotherapy - July 21, 2017 Category: Cancer & Oncology Source Type: research
Clinical Manifestations and Prognostic Factors of Pneumocystis jirovecii Pneumonia without HIV
Conclusion: We suggest that poor PS is an independent risk factor in non-HIV PCP, and a patient's PS and disease activity may correlate with outcome.Chemotherapy 2017;62:343-349 (Source: Chemotherapy)
Source: Chemotherapy - July 18, 2017 Category: Cancer & Oncology Source Type: research
Clinical Manifestations and Prognostic Factors of < b > < i > Pneumocystis jirovecii < /i > < /b > Pneumonia without HIV
Conclusion: We suggest that poor PS is an independent risk factor in non-HIV PCP, and a patient's PS and disease activity may correlate with outcome.Chemotherapy 2017;62:343-349 (Source: Chemotherapy)
Source: Chemotherapy - July 18, 2017 Category: Cancer & Oncology Source Type: research
High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy
Background/Aims: Doxorubicin (DOX) and trastuzumab (TRA) are associated with cardiac dysfunction.Method: High-sensitivity troponin T (hs-TnT) and brain natriuretic peptide attached to the amino acid N-terminal fragment in the prohormone (NT-proBNP) were measured before and on days +1, +2, +3, and +7 during cycles 1 and 2 of therapy with DOX or TRA in breast cancer patients.Results: Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs-TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs-TnT. Time to peak was...
Source: Chemotherapy - July 13, 2017 Category: Cancer & Oncology Source Type: research
Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common < b > < i > DPYD < /i > < /b > Polymorphisms
While the majority of patients can be treated safely with fluoropyrimidine, some experience severe fluoropyrimidine-associated toxicity. The frequency and severity of these adverse events vary from patient to patient and are partially explained by genetic polymorphism into the dihydropyrimidine dehydrogenase (DPYD) gene. Carriers of the rare allelic variantsDPYD*2A,DPYD*13, andDPYD D949V are more likely to experience severe adverse reactions during fluoropyrimidine-based therapy. However, these 3 genetic variants explain only a small percentage of the overall drug toxicity, and more frequent ones such as homozygous or comp...
Source: Chemotherapy - June 14, 2017 Category: Cancer & Oncology Source Type: research
